文献速递其他结缔组织病

托法替布治疗弥漫性皮肤型系统性硬化症皮肤增厚的疗效分析

Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

本研究纳入10例接受托法替布(5 mg每日两次)治疗的弥漫性皮肤型系统性硬化症(dcSSc)患者,并与12例接受强化传统免疫抑制剂治疗的历史对照患者比较。结果显示托法替布组mRSS在治疗第1个月即显著改善,6个月时改善程度优于对照组,且应答时间更短、应答率更高。提示托法替布对难治性dcSSc进展性皮肤增厚可能有效。

要点

  • 托法替布组mRSS第1个月即显著下降,平均变化-3.7(95%CI -5.52,-1.88;P=0.001)。
  • 6个月时托法替布组mRSS改善优于对照组(-10.0 vs -4.1,P=0.026)。
  • 托法替布组应答时间更短,1个月和3个月应答率分别为20% vs 0%和60% vs 16.7%。

核心结论

  • 托法替布对难治性dcSSc进展性皮肤增厚可能不劣于甚至优于强化传统免疫抑制剂,且起效更快、应答率更高。

研究设计与样本

  • 分析10例接受托法替布5 mg每日两次治疗的dcSSc患者数据,并选取12例接受强化传统免疫抑制剂治疗的历史患者作为对照。

主要发现

  • 托法替布组mRSS在治疗第1个月显著改善,平均变化-3.7(95%CI -5.52,-1.88;P=0.001)。
  • 6个月时托法替布组mRSS平均变化-10.0(95%CI -14.74,-5.26),对照组为-4.1(95%CI -7.49,-0.73),组间P=0.026。
  • 托法替布组应答时间显著短于对照组(log-rank检验P=0.015)。
  • 1个月和3个月总体应答率分别为20%(2/10)vs 0%(0/12)和60%(6/10)vs 16.7%(2/12)。

关键数值与推荐

  • 临床相关应答定义为mRSS较基线下降>5分且≥25%。
  • 托法替布用法为5 mg每日两次。

临床怎么用

  • 对于难治性dcSSc进展性皮肤增厚患者,托法替布可作为强化传统免疫抑制剂之外的一种潜在治疗选择。

局限性

  • 本研究为小样本回顾性分析,采用历史对照,证据级别有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To analyse the effectiveness of tofacitinib for the treatment of refractory skin thickening in dcSSc. METHODS: Data from 10 patients with dcSSc treated with tofacitinib (5 mg twice daily) were analysed. A total of 12 dcSSc patients treated with intensive conventional immunosuppressants were selected as the historical comparator group. A clinically relevant response was defined as a decrease in the modified Rodnan skin score (mRSS) of >5 points and ≥25% from baseline. Clinical indicators were compared between the two groups to evaluate the effect of tofacitinib. RESULTS: The mRSS significantly improved the first month after tofacitinib treatment, with a mean change in the mRSS of -3.7 (95% CI -5.52, -1.88; P = 0.001) and greater than the comparators at 6 months [-10.0 (95% CI -14.74, -5.26) vs -4.1 (95% CI -7.49, -0.73), P = 0.026]. Tofacitinib-treated patients had a significantly shorter response time than the comparators (P = 0.015 by log-rank test), with overall response rates of 20% (2/10) vs 0% (0/12) and 60% (6/10) vs 16.7% (2/12) at 1 and 3 months, respectively. CONCLUSION: Our results indicate that tofacitinib may be as effective as or even better than intensive conventional immunosuppressants, with a quicker and higher response rate in refractory dcSSc patients with progressive skin thickness.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. You H, Xu D, Hou Y, et al. Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford). 2021. PMID: 33188425. doi:10.1093/rheumatology/keaa613

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。